A sense of déjà vu: the debate surrounding state biosimilar substitution laws A sense of déjà vu: the debate surrounding state biosimilar substitution laws

Collection: Health Policy and Services Research Series Title(s): Insight on the issues (AARP Public Policy Institute) Author(s): Purvis, Leigh, author Contributor(s): AARP (Organization) Public Policy Institute (AARP (Organization)) Publication: Washington, D.C. : AARP Public Policy Institute, September 2014 Language(s): English Format: Text Subject(s): Biological Products -- economics Biological Products -- therapeutic use Biosimilar Pharmaceuticals -- economics Biosimilar Pharmaceuticals -- therapeutic use Drug Costs Drug Substitution Legislation, Drug United States United States. Food and Drug Administration United States. Genre(s): Technical Report Abstract: The Affordable Care Act created an approval pathway for less expensive generic versions of biologic drugs, known as biosimilars, or follow-on biologics. However, new state legislation that could greatly limit the savings from biosimilars has ignited a debate similar to the one that followed the passage of federal legislation that encouraged the development of traditional generic drugs. Copyright: Reproduced with permission of the copyright holder. Further use of the material is subject to CC BY-NC-ND license. (More information) Extent: 1 online resource (1 PDF file (5 pages)). NLM Unique ID: 101656652 (See catalog record) Permanent Link: http://resource.nlm.nih.gov/101656652